雷珠单抗与阿柏西普治疗糖尿病黄斑水肿的疗效对比  

Comparison of the efficacy of ranibizumab and aflibercept in the treatment of diabetic macular edema

作　　者：张燕妮 郭娟兰 李鑫鑫 ZHANG Yanni;GUO Juanlan;LI Xinxin(Qingyang Hospital of Traditional Chinese Medicine,Qingyang,Gansu 745000,China)

机构地区：[1]庆阳市中医医院,甘肃庆阳745000

出　　处：《现代医药卫生》2024年第19期3303-3306,共4页Journal of Modern Medicine & Health

摘　　要：目的探讨糖尿病黄斑水肿患者通过阿柏西普和雷珠单抗治疗的价值,以及比较2种药物对中央黄斑厚度(CMT)、最佳矫正视力(BCVA)和中央黄斑体积(CMV)的改善作用。方法选取2021年2月至2023年2月该院收治的100例糖尿病黄斑水肿患者,按信封随机法分成观察组(50例,50眼)、对照组(50例,50眼)。对照组施行雷珠单抗治疗,观察组施行阿柏西普治疗,对比2组疗效、CMT值、BCVA值、CMV值和并发症等。结果2组治疗总有效率比较,差异无统计学意义(P>0.05)。2组术前CMT值、CMV值比较,差异无统计学意义(P>0.05);观察组术后4、8个月CMT值、CMV值低于对照组,差异有统计学意义(P<0.05)。2组术前、术后4个月和8个月BCVA值比较,差异无统计学意义(P>0.05)。2组白内障、玻璃体积血和眼结膜炎等并发症发生率比较,差异无统计学意义(P>0.05)。结论在糖尿病黄斑水肿疾病的治疗中,阿柏西普和雷珠单抗均可取得一定疗效,但阿柏西普在减少CMT,缩小CMV方面的优势更明显,且并发症较少。Objective To explore the efficacy of treating diabetic macular edema with aflibercept and ranibizumab,and to compare the effects of these two drugs on central macular thickness(CMT),best-corrected visual acuity(BCVA),and central macular volume(CMV).Methods From February 2021 to February 2023,100 patients with diabetic macular edema were admitted to the hospital and randomly divided into two groups using the envelope method:the observation group(50 patients,50 eyes)treated with aflibercept,and the control group(50 patients,50 eyes)treated with ranibizumab.The efficacy,CMT,BCVA,CMV,and complications of the two groups were compared.Results There was no statistically significant difference in the overall efficacy between the two groups(P>0.05).There was no significant difference in the pre-treatment values of CMT and CMV between the two groups(P>0.05).However,the CMT and CMV values at 4 and 8 months post-treatment were significantly lower in the observation group than in the control group(P<0.05).There was no significant difference in BCVA values before treatment,and at 4 and 8 months after treatment between the two groups(P>0.05).The rates of complications such as cataract,vitreous hemorrhage,and conjunctivitis were similar between the two groups(P>0.05).Conclusion Both aflibercept and ranibizumab can be effective in treating diabetic macular edema.However,aflibercept has a more pronounced advantage in reducing CMT and decreasing CMV,with fewer complications.

关 键 词：阿柏西普 中央黄斑厚度 糖尿病黄斑水肿 最佳矫正视力 雷珠单抗 

分 类 号：R587.1[医药卫生—内分泌] R774.5[医药卫生—内科学]